Salvia miltiorrhiza Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets

Jie Liu1,2,3,4, Yun Shi1,2,3, Daiyin Peng1,2,3, Lei Wang1,2,4*, Nianjun Yu1,2,3, Guokai Wang1,2,3 and Weidong Chen1,2,3,4*

1 School of Pharmacy, Anhui University of Chinese Medicine, Hefei, China, 2 Anhui Province Key Laboratory of Chinese Medicinal Formula, Hefei, China, 3 Institute of Traditional Chinese Medicine Resources Protection and Development, Anhui Academy of Chinese Medicine, Hefei, China, 4 Anhui Province Key Laboratory of Traditional Chinese Medicine Decoction Pieces of New Manufacturing Technology, Hefei, China

Non-alcoholic fatty liver disease (NAFLD) is rapidly prevalent due to its strong association with increased metabolic syndrome such as cardio- and cerebrovascular disorders and diabetes. Few drugs can meet the growing disease burden of NAFLD. Salvia miltiorrhiza Bge. (Danshen) have been used for over 2,000 years in clinical trials to treat NAFLD and metabolic syndrome disease without clarified defined mechanisms. Metabolic targets restored metabolic homeostasis in patients with NAFLD and improved steatosis by reducing the delivery of metabolic substrates to liver as a promising way. Here we systematic review evidence showing that Danshen against NAFLD through diverse and crossing mechanisms based on metabolic targets. A synopsis of the phytochemistry and pharmacokinetic of Danshen and the mechanisms of metabolic targets regulating the progression of NAFLD is initially provided, followed by the pharmacological activity of Danshen in the management NAFLD. And then, the possible mechanisms of Danshen in the management of NAFLD based on metabolic targets are elucidated. Specifically, the metabolic targets c-Jun N-terminal kinases (JNK), sterol regulatory element-binding protein-1c (SREBP-1c), nuclear translocation carbohydrate response element–binding protein (ChREBP) related with lipid metabolism pathway, and peroxisome proliferator-activated receptors (PPARs), cytochrome P450 (CYP) and the others associated with pleiotropic metabolism will be discussed. Finally, providing a critical assessment of the preclinic and clinic model and the molecular mechanism in NAFLD.

Keywords: Danshen, non-alcoholic fatty liver disease, metabolic targets, pharmacokinetic, molecular mechanism

Abbreviations: ABC, ATP-binding cassette transporter A1; AP-1, activator protein-1; CAR, constitutive androstane receptor; C/EBP, CCAAT-enhancer-binding proteins; ChREBP, carbohydrate response element–binding protein; CT, cryptotanshinone; CYP, cytochrome P450; DNL, de novo lipogenesis; ERK, extracellular signal-regulated protein kinase; FGF21, fibroblast growth factor 21; FXR, farnesoid X receptor; GLUT-4, glucose transporter 4; JNK, c-Jun N-terminal kinases; LA, lithospermic acid; LXRα, liver-X-receptorα; MAPK, mitogen-activated protein kinases; NAFL, non-alcoholic fatty liver; NAFLD, Non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; NF-κB, nuclear factor-κB; OATPs, organic anion transporting polypeptides; PAA, protocatechuic acid; PCA, protocatechuic aldehyde; PPARs, peroxisome proliferator-activated receptors; PXR, pregnane X receptor; RA, rosmarinic acid; RXRα, retinoid X receptorα; SHP, small heterodimer partner; SAA, salvianolic acid A; SAB, salvianolic acid B; SAC, salvianolic acid C; SAD, salvianolic acid D; SREBP-1c, sterol regulatory element–binding protein-1c; SULT, sulfotransferases; STATs, signal transducers and activators of transcription; TCM, traditional Chinese medical; TI, dihydrotanshinone I; TSI, tanshinone I; TSIIA, tanshinone IIA; TSL, tanshinol; UGT, UDP-glucuronosyltransferases.
INTRODUCTION

NAFLD refers to a spectrum of liver diseases, which defined by steatosis in more than 5% of hepatocytes with little or no alcohol consumption (1). NAFLD is composed of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), which is characterized by steatosis, hepatocellular ballooning and lobular inflammation and accompanied by varying degrees of liver fibrosis (2). With the worsening of the fibrosis, some patients with NASH deteriorate to hepatic cirrhosis or even hepatic carcinoma. Currently, almost 25% of the general population worldwide suffer from NAFLD, and 20% of them will progress to hepaticcirrhosis as the disease deteriorates (3). NAFLD is a metabolic stress liver injury, and its main pathogenesis is insulin resistance and lipid metabolism disorders. Metabolic syndromes such as obesity, insulin resistance, hyperglycemia, dyslipidemia, and hypertension are the main risk factors for NAFLD. However, drugs that interfere with NASH have side effects such as pioglitazone for insulin resistance, vitamin E for antioxidants, (4), and the only approved treatment is hygiene and dietary measures to date. At present, the prescription of traditional Chinese medical (TCM) contribute to the improvement of lipid infiltration of the liver and of the related anthropometric, and biochemical parameters (5). Besides, TCM may be promising treatment strategies for NAFLD due to their relatively cost-effective, multiple targets and few side effects.

Danshen has been used widely to treat metabolic syndromes such as hypertension, dyslipidemia, and hyperglycemia, which is consisted of active constituents such as hydrophilic phenols, lipophilic diterpenoids and polysaccharides (6). Accumulating evidence has suggested that the preventive and therapeutic potential of Danshen on NAFLD is related to reducing the risk of metabolic disorder in preclinic and clinic trials (7–10). What counts is, the frequency of clinical use of Danshen reached 7.28% in treatment with NAFLD, second only to the peach kernel (11). A case in point is that 8 randomized controlled trials with 800 patients of NAFLD showed that Danshen relieved the degree of hepatosteatosis by significantly reducing the plasma levels of transaminases (9).

The pathogenic driver of NAFLD is that the imbalance between glucose and lipid metabolism leads to excessively accumulated lipids within the liver (12, 13). Metabolic targets can rebalance the metabolic disorders and improve steatosis by reducing the delivery of metabolic substrates to the liver in patients with NAFLD (14–16). Additionally, a large number of pharmacological studies have shown that drugs targeting metabolic targets can effectively treat NASH, which proves that metabolic targets would be a promising prospect therapy for the treatment of NAFLD (4, 17, 18). Previous reviews discussed the prominent metabolic targets of NAFLD pharmacotherapy, including lipid metabolism pathway modulator acetyl-CoA carboxylase (acetyl-CoA), nuclear receptors, thyroid hormone receptors, glycemic modulator, sodium-glucose co-transporter 2 and fibroblast growth factors, etc. (12, 19). Herein we focus primarily on the significant metabolic targets associated with Danshen, including c-Jun N-terminal kinases (JNKs), SREBP-1c, ChReBP, PPARs, CYPs and the others, to provide theoretical basis for the development of a new way of Danshen treatment of NAFLD.

PHYTOCHEMISTRY OF DANSHEN

We reviewed phytochemistry of Danshen to fully understand its roles in NAFLD. Over 200 chemical components including phenolic acids, diterpenoids and polysaccharides have been identified from this plant (20).

The phenolic acids of Danshen contain a core skeleton of phenylpropanoid (C6-C3). It is generally believed that the phenolic acids are mostly conjugated with (R)-3- (3,4-Dihydroxyphenyl)-2-hydroxy- propanoic acid and derivatives or dimer of caffeic acid (21). For instance, Salvinolic acid A (SAA) is composed of tanshinol (TSL) and two molecules of caffeic acid. Previous studies have clarified the phenolic acids bioactivities such as anti-inflammatory, anti-oxidative, cardio-protection activity (22).

As a representative of diterpenoids, tanshinones are comprised of naphthalene or tetrahydro naphthalene rings A and B, ortho- or para-naphthoquinone or lactone ring C, and a furan or dihydrofuran ring D (21). Among these, tanshinone IIA (TSIIA) and cryptotanshinone (CT), which are characterized by an ortho-quinone C-ring. TSIIA, CT, tanshinone I (TSI), and dihydrotanshinone I; (TI) as primary and marker constituents in the official Chinese Pharmacopoeia, which exhibit the biological activity of anti-oxidative, anti-inflammatory, and anti-diabetic (23).

Besides, polysaccharides, flavonoids, steroids, and phenan threnequinone have been identified in Danshen, which proved that a variety of pharmacological activity. For instance, the polysaccharides of Danshen exhibits immunomodulatory and antitumor effects (21).

In this article, we briefly presented the identified chemical structure in Danshen, which related to the pharmacological effects of NAFLD as Figure 1. Interested readers are inspired to know more compounds of Danshen refer to related reviews.

PHARMACOKINETICS

CHARACTERISTICS OF DANSHEN

Pharmacokinetics is a bridge linking herbal medicine and pharmacological responses. The active ingredients of Danshen exert therapeutic effects of NAFLD through entering the systemic circulation to reach the target organ or tissue. Painstaking efforts directed at mechanisms influencing the pharmacokinetics of Danshen can aid in improving their intended pharmacological activity. The major topics cover (i) Danshen ability to enter a system and how to metabolite and eliminate through various tissues, and (ii) what factors determine the course of Danshen bioavailability and how to improve it.

PHENOLIC ACIDS

Extensive research performed the complicated absorption mechanism of phenolic acids of Danshen. The gastrointestinal
FIGURE 1 | The compounds in Danshen related to the pharmacological effects of NAFLD.
absorption of rosmarinic acid (RA), salvianolic acid B (SAB), protocatechuic aldehyde (PCA) and TSL were characterized by passive diffusion in the intestine (24, 25). Besides, the paracellular absorption transport pathway also existed in SAB and TSL (26). The phenolic acids were of low bioavailability in animal or human plasma after oral administration, except for TSL. For instance, the oral bioavailability of SAB, salvianolic acid C (SAC), lithospermic acid (LA), salvianolic acid D (SAD), magnesium lithospermate B and miltirone were 1.07, 0.29, 1.15, 4.16, 0.02, and 3.4% in rats, respectively (27–31). Moreover, the concentration of Danshen preparations in plasma after oral administration slightly detectable in human subjects. Li et al. found that the $C_{\text{max}}$ of TSL, PCA and protocatechuic acid (PAA) in humans were 134.1 ± 48.4, 10.5 ± 5.6, and 59.0 ± 18.6 ng/mL after oral administration of Compound Danshen Dripping Pills (32). Researches showed that the poor bioavailability of phenolic acids was due to their adverse properties, including molecular mass, hydrogen bonding capacity and molecular flexibility (33). TSL has good properties and its bioavailability reaches to 30–40% in animals (34). Injection is more effective than oral administration. The TSL, SAD, LA, RA, PCA, and TSL exhibited considerable exposure in human subjects and rats after intravenous administration Danshen (35, 36).

Polyphenol compounds were transformed by colonic microflora and decomposed into simple phenolic acid derivatives, easily absorbed from the intestine. The major metabolites of phenolic acids were the methylated and their sulfated and glucuronide products in humans, rats and dogs, which may be responsible for the biological activity (37, 38). SAA, SAB, PCA, and LA were subject to extensive elimination mainly via hepatobiliary excretion of glucuronide and renal excretion (37). For example, SAB seemed to enter liver cells rapidly after oral or intravenous dosing, and methylated metabolites may exert antioxidant action. PCA was transformed into PAA in the liver and then eliminated by conversion into sulfates and methylated glucuronides followed by renal excretion (36). However, RA, TSL, and SAD were eliminated mainly via renal excretion, rather than hepatobiliary excretion (34, 39). Among these, RA could be broken down into smaller phenolic acids such as TSL and caffeic acid and eliminated by renal excretion in healthy human subjects (40). Further studies with the metabolic pathways of other component in Danshen preparations are required.

Several presystemic processes, including gastrointestinal solubility, membrane permeability, gastrointestinal degradation, transporter-mediated intestinal efflux, systemic intestinal wall metabolism, and hepatic metabolism, could lead to the low bioavailability of phenolic acids. Researchers have been trying to improve the bioavailability of Danshen such as ameliorating dosage form (e.g., sodium caprate and lipid nanoparticle formulations). For instance, the sodium caprate could significantly enhance the bioavailability of both TSL and SAB by improving intestinal permeability (26). When encapsulated into liposomes and chitosan nanoparticles, the $t_{1/2}$ and AUC$_{0-\infty}$ of SAB in beagle dogs were higher than that of free SAB (41, 42). Certain components in Danshen preparations can affect the pharmacokinetic behavior of other coexisting ingredients, which contributed to synergistic or metabolic transformation. Chang et al. observed that the AUC$_{0-8}$, CL and $t_{1/2}$ of TSL and SAB were significantly influenced by the content variation of the other major components in the Danshen injection (43). Moreover, the tanshinones affected the bioavailability and distribution of RA, SAB, and TSL, and accelerated the biotransformation of Sal B to TSL. Similarly, the phenolic acids could influence the biotransformation of CT to TSIIA and improve the bioavailability of TSIIA (44). Additionally, the common Danshen compound compatibility herbs such as borneol can also improve the bioavailability of Danshen (45). Therefore, it will be interesting to focus on the transformation or interaction of components between Danshen preparation in the future.

## TANSHINONES

Few studies have reported the absorption mechanism of tanshinones. Yan et al. elucidated that the transport mechanisms of TSIIA and CT were active transport or facilitated diffusion (46). Zhang et al. observed that CT was transported primarily via an active mechanism across the intestinal epithelium, a saturable process that could pump CT into the luminal side (47). Meanwhile, other studies reported that TSIIA might not exclude a passive transport process (48, 49) due to its low molecular weight (294 D) and high lipophilicity (logP = 6.1) (50). The plasma level of tanshinones is low, generally in the nM to the sub-μM range in animals after oral or injection. Here offers instances that, Yu et al. found that the oral bioavailability of tanshinone IIB (TSIIB) was about 3% in rats (51), and the $C_{\text{max}}$ of 0.274 μg/mL of TSI after intravenous injection at 3 mg/kg dose in rats (52). Additionally, the blood concentration of Danshen mixture was poor in rats, either. The $C_{\text{max}}$ of TSI, TI, TSIIA, and CT were 1.63 ± 0.78, 3.23 ± 1.40, 2.78 ± 0.96, and 0.66 ± 0.27 ng/mL after oral administration of PF2401-SF (the standardized fraction of Danshen, equivalent to TSI: TI: TSIIA: CT = 1.15:1.10:4.1:1.91 mg/kg) to rats (53). When a mixture of phenolic acids and tanshinones including TSL (10.25 mg/kg), RA (6.39 mg/kg), CT (9.82 mg/kg), TI (13.58 mg/kg), TSI (3.90 mg/kg), and TSIIA (5.79 mg/kg) were orally administered to rats, the $C_{\text{max}}$ of each constituent was 72, 37, 43, 11, 55, and 22 ng/mL, respectively (54). Exposure to tanshinones of granular powder formulation after a single oral administration in healthy volunteers, the $C_{\text{max}}$ of TSI, TSIIA, and CT was 6.57, 25.8, and 146.7 ng/mL, respectively (55). The low bioavailability of tanshinone is mainly due to the lack of molecules with high logP or optimal HLB values and permeability. Therefore, bioavailability enhancement improved the application of tanshinones in the clinic.

Previous investigation indicated that the concentration of tanshinones in bile was much higher than in plasma and urine, suggesting that the tanshinones are mainly metabolized in the liver (56). TSIIA is preferentially distributed into the liver after either intravenous or oral doses, which is due to the self-association or self-assembly of highly hydrophobic compound to form macromolecules or polymers and can be recognized and taken up by the reticuloendothelial system (48). TSIIA
underwent extensive CYP-mediated oxidation, and then subject to glucuronidation, after the glucuronides hydrolysis, aglycones are reabsorbed from the intestine and excreted into bile as a conjugate (57). TI was initially biotransformed into TSI and then shared the metabolic pathways, including glucuronidation, hydroxylation, reduction, methylation, and the O-sulfate conjugated reaction (58, 59). Hence, methylation, demethylation, dehydrogenation, hydrogenation, and hydroxylation were the major metabolic transformation of tanshinones.

The factors including poor solubility, poor permeability, and formulation, etc. resulting in low bioavailability of tanshinones. Similar to phenolic acids, the ultrafine powder and solid lipid nanoparticles formulations could improve the bioavailability of CT, TSIIA, TI, and TSI by enhancing their stability and permeability (60–62). On the other hands, components in tanshinone extracts also affected the pharmacokinetics of monomer constituents. Song et al. reported that tanshinone extracts synergically promoted the absorption of TSIIA and CT and accelerated the transformation of CT to TSIIA (63). The mechanism of promoting absorption and biotransformation between components in TCM formula should be further studied.

THE POLYSACCHARIDES OF DANSHEN

In addition to phenolic acids and tanshinones, polysaccharides of Danshen exhibited antioxidant, immunoregulatory, ameliorating metabolic disease, hepato-protective, and against NAFLD (64). Few studies involved pharmacokinetics of Danshen polysaccharides compared with the pharmacodynamics. This is related to the complex molecular structure, which lacks both chromogenic and light absorption groups, and susceptible to the interference of biological substances in concentration detection. What’s worse, it is well known that polysaccharides are poorly absorbed. Generally, there are three theories for the mechanism of oral absorption of polysaccharides: direct absorption, intestinal microflora absorption and intestinal Peyer collection lymph node absorption (65). Wang et al. concluded that ganoderma lucidum polysaccharide was ingested by pinocytosis in Caco-2 cells (66). And the elimination of polysaccharides is mostly by the kidney (67). Some researchers believe that polysaccharides work through direct absorption in the gut. A novel polysaccharide of Danshen, SMWP-U&E, improved the absorption of weaned piglets by increasing the diversity and evenness of the intestinal microflora after doses at 1.5 g/kg to the pigs (68). Lack of evidence regarding the mechanism of the pharmacokinetics of polysaccharides is a major barrier to realizing the full potential pharmacological activity.

DISCUSS THE ACTIVITY AGAINST NON-ALCOHOLIC FATTY LIVER DISEASE OF DANSHEN COMPOUNDS WITH LOW BIOAVAILABILITY

The phenolic acids, tanshinones, and polysaccharides isolated from Danshen exhibited various biological activity such as against NAFLD. However, how some Danshen compounds with low bioavailability exhibit their pharmacological activity against NAFLD. Here we attempt to interpret this from four aspects: (i) the chemical structure-activity of Danshen, (ii) the bioavailability of Danshen compounds in comparison between physiological and physiological condition, (iii) pharmacological activity of the improved bioavailability compound of Danshen, (iii) Danshen induced gut microbiota alteration.

THE CHEMICAL STRUCTURE-ACTIVITY OF DANSHEN

The preventive and therapeutic potential of Danshen on NAFLD is related to reducing the risk of metabolic disorders, including antioxidant, anti-inflammatory, immunoregulatory, etc. Normally, the chemical structures of phenolic acids influence their redox potential. Specially, polyphenols with two o-hydroxyl groups on an aromatic residue are more capable of scavenging free radicals than polyphenols with only one hydroxyl group (69). The other active constituents of Danshen, diterpenoids, were demonstrated to exert anti-inflammatory, immunosuppressive and antitumor activity. Quinone group and aromatic ring are the basic structure of tanshinone activity, and carbonyl may play an important role in its antitumor activity (37). Zheng et al. confirmed that the antiproliferative effects of abietane quinone diterpenoids against five cancer cell lines (70). On the other hand, in addition to the parent compounds, the metabolites usually exhibited pharmacological activity. For instance, the sulfate esters and glucuronides metabolites of phenolic acids were shown to retain part of their antioxidant properties (71). Therefore, many of the biological effects observed in animal or clinical studies may be explained by the microbial metabolites of those compounds. Much research effort is needed to evaluate the biological effects of the conjugated derivatives and microbial metabolites of polyphenolic acids and diterpenoids. Generally, the structure-activity relationship between polysaccharides and intestinal flora from molecular weight, glycosidic bond, and monosaccharide composition (72). However, Danshen polysaccharide has not been studied in this respect.

THE BIOAVAILABILITY OF DANSHEN COMPOUNDS IN COMPARISON BETWEEN PHYSIOLOGICAL AND PHYSIOLOGICAL CONDITION

The pharmacokinetics of Danshen formulation varies with pathological and physiological conditions due to the biological environment in the body. Accumulative studies have shown that the bioavailability of Danshen increased under pathological conditions compared to normal conditions. Shi et al. found that the plasma concentrations of TSL, PCA, PAL, SAC, SAB, and TSIIA and the AUC0−1, MRT0−1, and t1/2 of SAB and TSL in the middle cerebral artery occlusion rats were significantly increased compared with the sham-operated group (73). The CL of STS was lower in coronary heart disease patients than in healthy
volunteers in a population pharmacokinetic model study (74). Moreover, several metabolites of TSIIA presented differences in the distribution between the sham control and the Alzheimer's Disease Rat model (75). The pharmacokinetics of Danshen in the NAFLD disease state needs to be studied since several studies have demonstrated the altered pharmacokinetics of drugs in NASH patients (76).

**PHARMACOLOGICAL ACTIVITY OF THE IMPROVED BIOAVAILABILITY DANSHEN COMPOUND**

The modified Danshen compounds improved bioavailability and pharmacological activity. Li et al. reported that STS was a promising drug for treating NAFLD by decreasing lipid accumulation and suppressing inflammation (77). Moreover, TSIIA encapsulated into globin to form nanoparticles that could markedly attenuate the progression of hepatic fibrosis (78). The nanoparticle-containing TSIIA was significantly more effective in inhibiting tumor growth in mice with hepatoma than free TSIIA (79). The pharmacological activity of modified other compounds from Danshen need further study.

**DANSHEN INDUCED GUT MICROBIOTA ALTERATION**

Hypothesized mechanisms of how the gut microbiome contributes to the development of NAFLD by increasing intestinal permeability, leading to the release of lipopolysaccharide into the host, which can trigger tissue and systemic inflammation, and metabolite produced by microorganisms that can influence immunity (80, 81). Currently, increasing evidences showed that Danshen preparations and the monomer active components regulated intestinal flora. For example, the aerial parts of Danshen could imbalance the intestinal microflora disorder caused by diabetes (82). Wang et al. observed that SAA modulated gut microbiota imbalance during colitis by increasing the gut microbial diversity as well as selectively promoting some probiotic populations (83). Many preparations containing Danshen balanced the intestinal flora such as SMWP -U&E (68), BuZangTongLuo decoction (84), the mixture of yeyachun and Danshen (85). Among these, Danshensu Bingpian Zhi not only reversed HFD-induced intestinal microbiota dysbiosis but also stimulated brown adipose tissue browning and maintains intestinal barrier integrity (86). Previous studies indicated that microbiota composition is related to insulin resistance (87, 88). Probiotics and Danshen polysaccharide combination has the potential to be used as a therapeutic for ameliorating NAFLD via regrouping the composition of the intestinal microbiota and improvement of insulin resistance. In addition, Bacteroidetes/Firmicutes ratio can be increased by Danshen polysaccharide, which is a compositional biomarker for obesity and type 1 diabetes mellitus (89). Danshen preparation including Jian-Gan-Xiao-Zhi (90), DLT-SM (91), and GuanXinNing Tablet Decoction decreased the Firmicutes/Bacteroidetes ratio through regulation of host metabolism. Recent study has found the genera Muribaculaceae might be concerned with the resistance effect of lean mice to HFD (93). Meanwhile, the reduction of Erysipelotrichaceae may be beneficial to lipid metabolism (94). Dingxin Recipe IV increased the relative abundance of Muribaculaceae and decreased Erysipelotrichaceae, which is beneficial to lipid metabolism (95). However, the mechanism of those bacteria in the development of lipid metabolism remains unclear. Besides, there is an intense correlation between fecal microbiota and inflammatory factors. For example, TI enriched bacterial species which promote butyric acid metabolism or negatively correlated with inflammatory factors (89).

**DANSHEN IN MANAGEMENT OF DISEASE BASED ON METABOLIC TARGETS RELATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE**

Mechanisms of Metabolic Targets Regulating the Progression of Non-alcoholic Fatty Liver Disease

From the theory of "second two-hit" to "multiple hits," the pathogenesis of NAFLD only partially understood so far. When
determining the pathogenicity drivers of NAFL and NASH, elucidating the source and fate of fatty acids in hepatocytes is vital to interpret the metabolic basis of NAFLD. The liver acquires free fatty acids through de novo lipogenesis (DNL) and triglyceride lipolysis in adipocytes, as shown in Figure 2. Primarily, fatty acids are delivered from the blood to the liver through the lipolysis of triglycerides in adipose tissue, regulated by the insulin on adipocytes. Phosphorylation of JNKs in adipocytes dramatically impacts insulin signaling, which contributes to excessive delivery of lipids to the liver and leads to NASH. Secondly, the increased peripheral fatty acids and DNL also elevated liver lipid content in NAFLD. DNL can be pharmacologically inhibited by targeting synthetic enzymes, such as acetyl-CoA, SREBP-1c, ChREBP (12, 97).

Besides, nuclear receptors including PPARs, retinoid X receptorα (RXRα), liver-X-receptorα (LXRα), farnesoid X receptor (FXR), pregnane X receptor (PXR), and constitutive androstane receptor (CAR) regulated fatty acids (Figure 3) (98). Moreover, NAFLD is poised to have an appreciable impact on the expression and function of ATP-binding cassette efflux transport proteins (e.g., MRP), uptake transporters (e.g., OATPs), and metabolic enzymes such as CYP, UDP-glucuronosyltransferases (UGT) and sulfotransferases (SULT) (99–101).

The PPARα, PPARβ/δ, and PPARγ are members of the nuclear receptor PPAR super-family. PPARα, which is expressed at the high levels in the liver. The deletion of this gene gradually as NASH progresses accelerated the development of NAFLD in preclinical and clinic (102). The activation of PPARβ/δ regulated hepatic glycolipid metabolism in NAFLD (103). PPARγ is mainly in adipose tissues, where its ligands enhanced adipocyte storage of fat and contributed to improve NASH (104). In short, PPARs exerted functions in glucose and lipid metabolism, inflammation, and fibrosis by modulating the expression of specific target genes (105). Indeed, the fibroblast growth factor 21 (FGF21) is an effective metabolic modulator of hepatic glycolipid homeostasis and insulin sensitivity, and PPARs directly induces FGF21 expression in the rodent liver (106, 107). Besides, activated PPARα may negatively interfere with the activity of pro-inflammatory transcription factors such as activator protein-1 (AP-1), signal transducers and activators of transcription (STATs), and nuclear factor-κB (NF-κB) and therefore repressing fibrosis progression (108–110). For instance, PPARα-agonists, fribates, have shown vital benefit in treating cardiovascular disease in clinical (111) and NAFLD in rodents (112). However, the efficacy of frribates on NAFLD treatment in humans has not been clarified. Moreover, PPARs modulated lipid dysregulation and inflammatory by adiponectin. Overexpression of PPARγ detected in NAFLD, which is potentially due to adiponectin (113, 114). Researches showed that the agonists of PPARγ against NAFLD might attributed to induce adiponectin (115, 116).

FXR, the bile acid receptor, negatively modulated bile acid synthesis and reduced hepatic gluconeogenesis, lipogenesis and steatosis at both hepatic and extrahepatic tissues (117). The hepatic expression of FXR downregulated in NAFLD patients. Activated FXR appears to influence insulin sensitivity and lipoprotein transport at multiple levels, which indicated that FXR holds promise as targeted therapeutic (118). FXR regulated hepatic bile salt synthesis by stimulating FGF15 (a hormone with direct glycogen synthesis in the liver and distant organs, FGF19 in humans) expression in the intestinal and repressing CYP7A1 in the liver (119, 120). Activated FXR improved hepatic glycogen synthesis via inducing FGF15 in mice (121). Of note, FXR agonist CDCA affected glucose homeostasis by controlling the expression of glucose transporter 4 (GLUT-4) (122). Meanwhile, activation of FXR also suppressed the formation of hepatic lipid and stimulated FAβ-oxidation to limit lipid accumulation. At present, BA-derivative OCA (FXR agonists) has been studied in patients with NAFLD, and further studies are needed to better define the clinical usefulness of OCA in NASH (123).

LXR regulated liver cholesterol homeostasis, inflammation, and fibrosis in vitro and in patients with NAFLD (124, 125). LXRα is responsible for lipid metabolism mainly in the liver, whereas LXRβ expressed ubiquitously (126). Higuchi et al. observed that the expression of LXRincreased in patients with NAFLD (127). Morin, a dual antagonist of LXRα and LXRβ, alleviated hepatic steatosis and metabolic disorders via the suppression of LXR signaling (128). Namely, LXR antagonism may be productive for attenuating hepatic steatosis and ensuing fibrosis. PXR and CAR are xenobiotic-sensing nuclear receptors that modulated the expression of genes such as CYPs, UGTs, and OATPs (129). More recently, PXR and CAR participated in regulating glucose, lipid, and bile acid metabolism, and highly expressed in the liver and gut (130). Previous studies have shown that activated PXR and CAR worsen the hepatic steatosis and insulin resistance in NAFLD by suppressing gluconeogenesis and β-oxidation and increasing hepatic fatty acids uptake (131, 132). Indeed, PXR also regulated SREBP1 and PPARα involved in metabolic homeostasis (133, 134), and CAR targeted CYP2B6 (99). For example, a study demonstrated that SREBP-1 inhibited drug-mediated induction of CYP2B and CYP3A via activating PXR and CAR in rodents, which indicated that PXR and CAR respond to lipid accumulation through direct interaction with SREBP-1 (135).

Due to its progressive nature and its significant impacts on hepatic histopathology, NAFLD is expected to significantly affect transporters and metabolic enzymes such as CYPs, UGTs, and SULTs. The expression and function of transporters such as OATPs and MRP changed with NAFLD progressing in humans and animals. This change affected the plasma and tissue disposal of endogenous and exogenous compounds (136). It seems to be that the CYP2E1 and CYP3A have been identified as the most relevant enzyme due to the vital role of oxidative stress in NAFLD (137). The induction of CYP2E1 is an adaptive response, which prevented lipid overload in NAFLD. While the increased CYP2E1 and improved insulin resistance appear to stimulate each other, that may ultimately worsen the process of steatosis with the increase in oxidative stress (138). However, the mechanism is not clarified yet. CYP3A genes appear to be regulated by various signaling pathways such as CCAAT-enhancer-binding proteins (C/EBP), HNF, PXR, and CAR, Janus kinase/signal transducers and activators of transcription (JAK/STAT), and mitogen-activated protein kinases (MAPK) pathway (19). However, few study have been reported that elucidating the shifts in the drug metabolism and bile
The mechanisms of major metabolic targets regulating the progression of NAFLD. PPARs: The FGF21 directly targeting PPARs key pathogenesis of NASH are hepatic free fatty acids. And activated PPARα may negatively interfere with the activity of pro-inflammatory transcription factors AP-1, STATs, and NF-κB. PPARγ attenuates inflammation via inhibiting NF-κB activity and elevating FGF21 in adipose tissue. FXR: FXR regulates hepatic bile salt synthesis through stimulating FGF15 (FGF19 in humans) expression in the intestinal and repressing CYP7A1 in the liver. LXR: Inhibition of LXRα via SREBP-1c contributes to alleviate progress of hepatic steatosis. PXR and CAR: PXR and CAR regulates SREBP1 involved in metabolic homeostasis.

acid associated with UGTs and SULTs enzymes in NAFLD to date. Hardwick et al. showed minimal alterations in the activity of UGTs while several changes in the expression and function of specific SULT during human NAFLD progression (101). The bile acid-related enzymes UGT and SULT2A1 were strongly suppressed in high-fat-cholesterol-fed males (139, 140). Expression and functional of transporters changed in NASH patients. OATP1B1 and OATP1B3 downregulated, MRP3 and MRP4 upregulated and MRP2 mislocalized in NAFLD (141). The mechanism is that the loss of glycosylation of the transporters (142).

The Pharmacological Activity of Danshen in the Management of Non-alcoholic Fatty Liver Disease
Concerning the therapy for NAFLD, we focus mostly on risk factors such as metabolic syndrome, including overweight, hyperglycemia, insulin resistance, dyslipidemia, and hypertension (143). Conversely, the NAFLD may strengthen some features and comorbidities of the metabolic syndrome. Especially, cardiovascular diseases are the main causes of mortality of the patients with NAFLD (5). Thus, effective treatment of NAFLD and metabolic syndrome could have mutual benefits for each other. Danshen is a highly versatile and multi-activity herb that can significantly limit the processes of liver diseases. Clinical trials of Danshen effectively treat NAFLD and metabolic syndrome (9, 10, 144). More evidence indicated that Danshen and their derived compounds limited the progression of hepatic steatosis of NASH in animals and in vitro (145–147). For example, Danshen tablets combined with Alovastatin significantly alleviated fatty liver cirrhosis and cardiovascular atherosclerosis caused by abnormal lipid metabolism in NAFLD treatment (148). Danshen polysaccharides combined with Probiotics regulated lipid metabolism disorders and protected the liver in NAFLD mice (8). Conclusively, the preventive and therapeutic potential of Danshen for NAFLD is related to reducing the risk of metabolic disorders.

A variety of mechanisms in inhibiting hepatic steatosis and modulating lipid metabolism have been shown by the compounds of Danshen and its preparations (Table 1), including the regulation of hepatocyte apoptosis via inducing autophagy in an AMPK-dependent way (149), the modulation of lipid metabolism via activating ChREBP (146), PPARα (7), PXR (150) or inhibiting PPARγ (151) and LXR (95), anti-inflammation through inhibiting Nrf2 (152) and JNK (153), anti-oxidative stress by activating Nrf2 and suppressing CYP2E1 (154), anti-fibrosis through inhibiting MAPK (155), regulating NF-κB/IκBα (156), activating Wnt/β-catenin (157) and SIRT1/HSF1 (158) and improving the insulin resistance (159). For instance, SAB against hepatocyte apoptosis by upregulating the mortalin, a protein of maintaining mitochondrial homeostasis (160). CT exhibits a hepatoprotective effect by activating Nrf2 and AMPK/SIRT1 and inhibiting CYP2E1 (161). SAB could effectively inhibit liver fibrosis with 60 patients (162). Potentially, the combination of Danshen Polysaccharide and Probiotics ameliorated NAFLD via controlling the gut microbiota and insulin resistance (8). In particular, the genes including JNKs, SREBP-1c, ChREBP, PPARs, CYPs, and the others have been highlighted as crucial molecular targets for Danshen treating patients with NAFLD (Figure 4).
TABLE 1 | The metabolic targets involved in treating NAFLD of Danshen.

| Herb | Animal/cell model | Dose | Targets/pathways/mechanisms |
|------|-------------------|------|-----------------------------|
| CT   | HepG2 and MEF, A549, DU145, AGS, and HCT116 cells | 5–10 mM | AMPK |
| Danshen | CDAA diet-induced mice | 0.003–0.84 g/kg | PPARα/JNK |
| TSIIA | Lipopolysaccharide-induced hepatic stellate cells | 1–10 mM | JNK and JAK/STAT |
| TSIIA | Lipopolysaccharide-induced ATDC5 cells | 5–20 µM | JNK and JAK/STAT |
| CT   | Sodium-nitroprusside-induced neuro-2a cells | 10–20 µM | ERK1/2 and JNK |
| Tanshinlactone A | Human peripheral blood mononuclear cells | 6.25–100 M | ERK, p38, and JNK |
| TSIIA | Lipopolysaccharide-induced RAW 264.7 cells | 1–10 µg/mL | NF-κB, p38, ERK1/2, and JNK |
| SAC  | APAP-induced mice | 5–20 mg/kg | AP-1 and JNK |
| 15,16-dihydroxytanshinone I | U2-OS, HK293T, HK-2, and MIN6 cells | 2.5–20 µM | Acetyl-CoA, AMPK |
| SAA  | Hyperlipidemic rats | 10 mg/kg | miR-33a and SREBP2/Pcsk9 |
| TSIIA | Lipopolysaccharide-induced-RAW 264.7 cells | 1–10 µg/mL | GLUT-1, GK, GLUT-4, and SREBP-1c |
| TSIIA | Lipopolysaccharide-induced-RAW 264.7 cells | 1–50 µM | RXRα |
| SAC  | APAP-induced mice | 100 mg/kg | NRF2/HO-1 and PPARγ/Angptl4 |
| 15,16-dihydroxytanshinone I | U2-OS, HK293T, HK-2, and MIN6 cells | 2.5–20 µM | Acetyl-CoA, AMPK |
| SAB  | Ethanol induced rats | 15–30 mg/kg | SIRT1/CRP and ChREBP |
| TSIIA | High fat diet induced mice | 1–2 µL/kg | acety-CoA and PPAR-α |
| TSIIA | High fat diet induced mice | 3 µg/kg | PPARα and 4-Hydroxynonenal |
| TSIIA | High calorie food induced mice models | 0.4–0.8 g/kg | RXRα |
| SAA  | Prednisone in adriamycin-induced rats | 10 mg/kg | NRF2/HO-1 and PPARγ/Angptl4 |
| SAA  | Prednisone in adriamycin-induced MPC5 cells | 50 µmol/l | PPARγ/Angptl4 |
| RA   | Ligation and scission of the common bile duct- induce mice | 0.1 mg/25 g | Wnts/PPARγ |
| TSIIA | Preadipocyte3T3-L1 cells high-fat diet induced mice | 5–60 µM | PPARγ |
| TSIIA | Human adipose fibroblast cells | 0.1–30 µM | PPARγ |
| SAB  | High-fat diet mice | 100 mg/kg | PPARγ/C/EBPα, GATA-2 and GATA-3 |
| SAB  | High-fat diet mice | 100 mg/kg | PPARγ/SREBP-1, C/EBPα |
| CT   | Preadipocyte3T3-L1 cells | 2–10 µM | PPARγ/STAT3 |
| CT Preparation Danshensu Bingpian Zhi | High fat diet mice | 50–100 mg/kg | PPARγ |
| 2-(3-methoxy-4-hydroxyphenyl)-6-(3-hydroxypropyl)-5-methoxybenzo[b]furan | Preadipocyte3T3-L1 cells | 1–25 µM | PPARγ/C/EBPα |
| PCA  | Human adipose fibroblast cells | 10–100 µM | PPARγ/C/EBPα, C/EBPβ |
| SAB  | Preadipocyte3T3-L1 cells | 50 µM | PPARγ/C/EBPα, C/EBPβ |
| Danshen extract | Carbon tetrachloride-induced rats | 10–100 mg/kg | CYP2E1 |
| CT   | Ethanol- induced mice | 20–40 mg/kg | AMPK/SIRT1, CYP2E1 |
| Polysaccharides of Danshen | CCL4-induced primary hepatocytes | 100 µg/kg | ALT, AST, malondialdehyde, GSH, and CYP450 |
| TSIIA | Acetaminophen-induced mice | 10–30 mg/kg | NRF2/GCLC, HO-1 |

POSSIBLE MECHANISMS OF DANSHEN IN MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE BASED ON METABOLIC TARGETS

Fatty Acids in the Non-alcoholic Fatty Liver Disease Control the Activity or Expression of Key Metabolic Targets

c-Jun N-terminal kinases

JNK is a critical mediator of insulin resistance, which leads to NASH through dysregulated lipolysis causing excessive transmit of fatty acids to the liver and intracellular accumulation of toxic lipid products that impair insulin signaling and activate inflammatory pathways (163). Several compounds of Danshen exhibits hepatoprotection and anti-inflammatory and subsequently against NAFLD through JNK-related signaling pathways. TSIIA, TSL, and SAB alleviated NAFLD progression through targeting PPARα and PPARγ/JNK signaling pathways. TSIIA inhibited phosphorylation of JNK on lipopolysaccharide-induced rat hepatic stellate cells, and TSIIA exhibited stronger effects of hepatoprotection than SAB (228). Similarly, CT effectively against apoptosis by blocking the activation of extracellular signal-regulated protein kinase (ERK)1/2, NF-κB.
and JNK signaling pathways (165). Additionally, Tanshinlactone A, a new diterpenoid tanshinone compound from Danshen, which against inflammation through inhibiting the ERK, p38 and JNK in cells (166). NF-κB regulated inflammation by phosphorylation of IκB via activation of the p38, ERK1/2 and JNK (167). TSIIA (168) and SAC (169) presented the anti-inflammatory activity through the signaling pathways mentioned above.

**Sterol Regulatory Element-Binding Protein-1c**

Free fatty acids are central to the pathogenesis of NASH. The main source of fatty acids from food or synthesized by acetyl-CoA through complex reactions including glycolysis and citric acid (170). AMPK is an energy mediator, which controlled cellular lipid metabolism. Phosphorylation of acetyl-CoA promoted adipogenesis by deactivating AMPK and inhibiting lipid oxidation (171). TI potently enhanced acetyl-CoA phosphorylation which caused decreased lipogenesis (172). Moreover, PPARα is one of the major downstream targets of AMPK (173). SAB relieved dyslipidemia and hyperglycemia partly by modulating the acetyl-CoA and AMPK/PPARα in db/db mice (174). Moreover, AMPK interacted with SREBP-1c and SREBP-2 and directly phosphorylated in diet-induced insulin-resistant mice (175). SREBP-1C, a major transcriptional regulator of the acetyl-CoA in the process of synthesis, could benefit the treatment of NASH (12). And signal transducer and activator of transcription (STAT-3) related to lipid synthesis by modulating the expression of SREBP-1C (176). Salvinolic acids significantly balanced the lipid metabolism disorders by inhibiting STAT-3 via suppressing the expression of SREBP1 (177). Meanwhile, SREBP-2 regulated the expression of Pcsk9 in hepatic cholesterol (178). A miRNA located in the SREBP-2 gene, microRNA (miR)-33, modulated lipid metabolism through regulation of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) (179). TSIIA ameliorated lipid accumulation in the hyperlipidemic rats via modulating the miR-33a and SREBP2/Pcsk9 pathway without impacting the lipid profile serum (180). Besides, the combination of herbs usually exerted synergistic effects. Danshen-Sanqi prescription increased the expression of hepatic glycogen synthesis gene, GLUT-1, GK, and GLUT-4, and reduced SREBP-1c gene related to fat and cholesterol anabolism (181). Generally, downregulation of SREBP-1C expression is likely due to the modulate of FXR (12). Besides, LXRα, SREBP-1c and acetyl-CoA regulated fatty acid and cholesterol synthesis through the tricarboxylate transport system (182). For instance, Dingxin Recipe containing Danshen regulated lipid metabolism by LXRα/SREBP1 but not LXRβ and SREBP2 in ApoE-/- mice fed with a high-fat diet (95).

**Carbohydrate Response Element–Binding Protein**

Theoretically, ChREBP induced the expression of the acetyl-CoA involved in DNL in NAFLD conditions (183). SAA alleviated hepatic lipid accumulation of high-fat diet-induced NAFLD rats partially due to the cross-talk mechanism between ChREBP and Thioeudrinox-interacting protein (TXNIP) (146). SAB played a critical role in anti-steatotic and anti-inflammatory by activating SIRT1-mediated suppression of CRP (C-reactive protein, HNF-1α promoter) and ChREBP expression in rats (184). However,
Further, PPARα through PPARγ liver increased as steatosis develop in rodents. SAA combined lipopolysaccharide-induced the decreased gene expression of α of RXRα as peripheral adipose tissue that reduced their transport to Diversion of fatty acids away from liver into other tissues such as hepatic tissues. Peroxisome Proliferator-Activated Receptors Diversion of fatty acids away from liver into other tissues such as peripheral adipose tissue that reduced their transport to liver. PPARα has emerged as lipid sensors that transcriptionally modulated the metabolic process (104). PPARα and PPARγ are PPAR isoforms, which exhibited distinct functions.

PPARα is activated by fibrates and modulated the adaptive response to nutritional inputs by regulating fatty acid delivery in the liver. Furthermore, the mRNA level for PPARα progressively reduced as NASH progresses in humans (102). Hence, PPARα activation is central to the remission of hepatic steatosis and NAFLD progression. Recent studies demonstrated that the active constituents of Danshen and related preparations enhanced PPARα in the livers of rodents and thus reduced lipid accumulation. For instance, a pharmacological network analysis suggested that the mechanism of hepatoprotective effects of TSIIA, TSL, and SAB may involve modulating lipid metabolism and anti-fibrogenesis via PPARα, CYP1A2, and MMP2 (7). Besides, Danhong injection significantly enhanced lipolysis and diminished fatty acids’ synthesis in the liver by increasing the mRNA transcription of PPARα in hyperlipidemia rats (186). Of note, cellular protection is associated with activated PPARα involvement in 4-Hydroxynonenal metabolism (187). Ding et al. found that Danshen injection played a mechanistic role in hepatoprotection in mice via inducing the activation of PPARα and subsequent degradation of 4-Hydroxynonenal (188). Worth the while, 4-Hydroxynonenal degradation promoted by PPARα activation is likely to relate with multiple enzyme systems, which deserves further study. In addition, the action of RXRα as a heterodimer partner with PPARα promoted the expression of RXRα that mediated fatty acid transport to mitochondria and oxidation (189). Yin et al. found that TSIIA reversed lipopolysaccharide-induced the decreased gene expression of RXRα (190). Nevertheless, the proof of other ingredients of Danshen has not been brought yet.

In contrast to PPARα, the expression of PPARγ in the liver increased as steatosis develop in rodents. SAA combined with prednisone exhibited therapeutic and antiproteinuric effects on adriamycin-induced minimal change disease rat model through PPARγ/Anap1l4 and Nrf2/Heme oxygenase-1 (HO-1) pathways (191). Further, PPARγ is considered as a downstream transcriptional target of Nrf2 in adipocytes differentiation (192). Hence, the influence of SAA modulated PPARγ/Anap1l4 pathway is directly associated with Nrf2 could be studied in future. Wnt10b is a direct target of nectarin, and neddin-Wnt pathway induced trans-differentiation of hepatic stellate cells through epigenetic inhibition of PPARγ (193). RA against liver fibrosis via inhibiting the expression and signaling of canonical Wnts/PPARγ in hepatic stellate cells (151). Similarly, it has been shown that SAB moderated lipid disorders by suppressing PPARγ-mediated adipogenesis in mice with high-fat diet-induced obesity (194). TSIIA inhibited adipogenesis as a natural antagonist of PPARγ in high-fat diet-induced obese mice (195). CT was demonstrated as an effectively anti-adipogenesis candidate through a multimodal signaling pathway-related to PPARγ (196). Moreover, PCA,2-(3-methoxy-4-hydroxy-phenyl)-6-(3-hydroxypropyl)-5-methoxybenzo[b]furan (an active compound identified from Danshen) and Danshensu Bingpian Zhi are efficient natural PPARγ agonists that exhibited excellent effects on insulin resistance, antiadipogenic, hepatic steatosis and inflammation (197, 198).

The Role of CYP450 Enzymes in the Pathogenesis of Non-alcoholic Fatty Liver Disease Patients with NAFLD are more susceptible to drug-induced toxicity due to altered drug metabolism (19). Previous workers reviewed the change of human hepatic CYP450 enzymes in NAFLD, such as CYP2E1,3A4, 1A2, 2A6, 2B6, 2C8, 2C9, and 2C19 (199). Generally, it seems to be that the alter in CYP2E1 and 3A4 activity is predominant in clinic studies (19, 200). CYP2E1 is related to the regulation of oxidant stress, insulin resistance and fatty acids, and the expression of hepatic CYP2E1 enhanced in patients with NAFLD (201). Danshen aqueous extracts containing TSL and SAB protected hepatocytes from Paracetamol-induced injury via remaining mitochondrial metabolic activity and suppressing the activity of CYP2E1 and total glutathione depletion (202). As mentioned above, CT and SAC reduced the content of CYP2E1 (161, 169). Previous studies about the expression and function of CYP3A4 associated with NAFLD are a contradiction. Recently, the recent consensus is more in favor of the protein expressions and mRNA of CYP3A decreased in NAFLD (203, 204). CYP3A4 is in charge of the oxidative metabolism of over 50% of all drugs prescribed in NAFLD (203). CT and TSIIA activated PXR and subsequently induced CYP3A4 (205). CYP1A2 promoted the generation of ROS to facilitate oxidative damage further. And the active ingredients of Danshen, isoimperatorin and oleanolic acid attenuating oxidative stress by modulating the expression of CYP1A2, 2B6, and 1B1 in the liver (7). TSIIA protected against lathocholic acid-induced liver cholestasis due to the upregulation of PXR, as well as CYP3A11, CYP3A13, and MDR1 (150). Additionally, Danshen polysaccharides exhibited preventive success on the injury of chicken hepatocytes via reducing the contents of ALT, AST, and malondialdehyde and upregulating GSH and CYP450 (206).

The Role of the Other Proteins in the Pathogenesis of Non-alcoholic Fatty Liver Disease Similar to CYPs, Phase II drug metabolic enzymes including UGTs, SULTs, and transporters (e.g., OATPs, MRPs) play various regulatory roles in NAFLD. UGT1A6, UGT1A9, and SULT1A1, SULT2A1 protein levels were downregulated in the liver of NASH patients (101, 139). Literature reports that the tanshinones are the inhibitors/substrates of UGT1A6 and UGT1A9 (207). However, whether Danshen treating NAFLD through UGTs and SULTs remains unclear. Besides, the induction of phase II detoxification enzymes HO-1 and glutamate-Lcysteine ligase catalytic subunit (GCLC) plays an antioxidant role in the Nrf2 pathway in NAFLD (208). TSIIA alleviated acetaminophen-induced liver injury by
activating Nrf2 and its target genes such as GCLC and HO-1 (209). Additionally, the expression and function of OATPs changed with the disease progression of NAFLD, and LA, RA, SAA, SAB, SAD, and TSL are potent inhibitors of OATP1 and OATP3 (210, 211). It is worth mentioning that the other metabolizing enzymes and transporters of drugs altered in NASH patients when compared with healthy human livers, and the change deserves to explore to prevent adverse drug reactions.

Clinic Studies
Clinical trials have shown that Danshen improved NAFLD therapy. Danshen prescriptions such as Danshen powder injection, Danning tablet and Sangming Mixture are effective in patients with NAFLD by improving the symptoms, liver function and blood lipids with no serious side effects (10, 202, 213, 226). Hu et al. observed that Yindan Xinnaotong Soft Capsule is effective in the treatment of NAFLD by regulating lipid and insulin resistance and liver function and anti-inflammatory (214). Hence, the herbal formula that have proved to take positive effects on the physiological features of NAFLD. Clinically, the combination therapy of Danshen and other agents including probiotics (e.g., Bacillus subtilis enterococcus dual living bacteria capsule) (164), hepatic protectants (e.g., Magnesium isoglucyphosphatidyl choline, Reduced glutathione, Tiopronin) (215–217), statins (e.g., Alvastatin) (148), and even the apparatus Bacillus subtilis dual living bacteria capsule and enterococcus exhibit more effective in patients with NAFLD (218). Although claimed to be hepatoprotective in NAFLD, the molecular mechanisms of combination therapy with Danshen have not been clarified, further multicenter large-sample randomized clinical trials are required to confirm the therapeutic and safety.

SAB regulated insulin resistance mainly through the AMPK/GLUT4 and/or SREBP-1/PPARγ signaling pathway, and modulated fatty acids through PPAR-mediated pathways, and exerted the effect of anti-inflammatory by STRT1/chREBP. TSIIA exhibited the role of anti-inflammatory anti-oxidant by regulating signals such as MAPK, JAK/STAT, and PXR/CYP and modulated fatty acids through PPARγ and SREBP pathways. CT exerted the effect of anti-oxidant by CYP2E1 and regulated fatty acids through AMPK and PPAR-mediated pathways. SaliA and SaliC rebalance the lipid metabolism by PPARγ and CYP2E1, respectively. RA prevented liver fibrosis by PPARγ pathways. Each color represents a compound, and dotted line indicates inhibition effects.

FUTURE PROSPECTS
Although steady progress has been made in elucidating the pathogenesis of NAFLD, determining therapeutic targets and advancing drug development, there are still unresolved challenges. To determine the molecular mechanisms, discern potential therapy targets, and guide the preclinical use of single or drug combinations, more studies are urgently needed using in vitro and animal NAFLD models. Many advances in the development of preclinic models such as in vitro models and genetic and dietary animal models for NAFLD have been made that have provided valuable insights on disease pathogenesis. However, only a few models resemble the key elements needed to be representative of NAFLD, while there exists a substantial difference between rodents and humans, such as the metabolic and transcriptomic characteristics, including the altered immune system and the altered glycolipid metabolism (219). Furthermore, no published data indicate that if drugs are effective in a given model, they consistently translate into efficacy in humans (220, 221). In addition, the heterogeneity of NAFLD according to sex, ethnicity and geographic region should be taken into consideration by researchers for clinic trials (222). Besides, the poor bioavailability, the most appropriate doses, the optimal route of administration, frequency of drug administration and the duration of treatment by Danshen are needed for various animal models to study comprehensively. Specifically, it is vital to focus on the experiment design, such as group size, controls and animal species.

Moreover, the tendency of this field is moving rapidly toward combination therapies, likely due to concern about insufficient ability to attack a single target, as shown that combining herbal medicine with other interventions presented better beneficial effects than interference alone (223). Besides, it is expected that researchers should discover more potent interplayed targets to increase synergy effects in future, such as PPARα agonist + PPARγ agonist, FXR agonist + PPARγ agonist, and PPAR pan-agonist + LXR antagonist (224).

Finally, the verification of predictive biomarkers of disease risk is lacking and urgently needed. Importantly, genetic risk factors such as the PNPLA3 gene have been identified that increase the NASH risk (225).

AUTHOR CONTRIBUTIONS
JL, YS, DP, NY, GW, LW, and WC wrote and contributed to the writing of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING
This work was supported in part by the Program of National Key Research and Development (2017YFC17016000), the Special Project of Anhui Province's Central Government to Guide Local Scientific and Technological Development (20107d0700002), the Natural Science Foundation of Anhui Province (1908085QH351), and the University Natural Science Research Project of Anhui Province (KJ2021A0586).

ACKNOWLEDGMENTS
We thank the members of the Laboratory YS, and the teachers DP, NY, GW, LW, and WC for guideline and discussion during this work.
REFERENCES

1. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. *Hepatology*. (2011) 54:344–53. doi: 10.1002/hep.24376

2. Kleiner DE, Makhoul HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. *Clin Liver Dis.* (2016) 20:293–312. doi: 10.1016/j.cld.2015.10.011

3. Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: what we need in the future. *Liver Int.* (2018) 38(Suppl. 1):47–51. doi: 10.1111/liv.13643

4. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med.* (2010) 362:1675–85.

5. Cicero A, Colletti A, Bellentani S. Nutraceutical approach to non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. *Nutrients.* (2018) 10:1153. doi: 10.3390/nu10091153

6. Tan Y, Kamal MA, Wang ZZ, Xiao W, Scale JP, Qu X. Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. *Clin Sci (Lond).* (2011) 120:297–305. doi: 10.1042/CS20100441

7. Hong M, Li S, Wang N, Tan HY, Cheung F, Feng Y. A biomedical investigation of the hepatoprotective effect of radix salviae miltiorrhizea and network pharmacology-based prediction of the active compounds and molecular targets. *Int J Mol Sci.* (2017) 18:620. doi: 10.3390/ijms180330620

8. Wang W, Xu AL, Li ZC, Li Y, Xu SF, Sang HC, et al. Combination of probiotics and *Salvia miltiorrhiza* Polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice. *Diabetes Metab J.* (2020) 44:336–48. doi: 10.4093/dmj.2019.0042

9. Peng H, He Y, Zheng G, Zhang W, Yao Z, Xie W. Meta-analysis of traditional herbal medicine in the treatment of nonalcoholic fatty liver disease. *Cell Mol Biol.* (2016) 62:88–95.

10. Sang XF. Effect evaluation of hepatopathy therapeutic apparatus combined with compound danshen injection in treatment of non-alcoholic steatohepatitis. *China Med. Mod.* (2013) 20:23–5.

11. Guo MY. Based on the Literature Review of Non-alcoholic Fatty Liver, the Relevant Research Between Prescription and Syndrome. Harbin: Heilongjiang University of Chinese Medicine (2019).

12. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. *Nat Med.* (2018) 24:908–22. doi: 10.1038/s41591-018-0104-9

13. Musso G, Cassader M, Gambino R. Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. *Nat Rev Drug Discov.* (2018) 17:1153. doi: 10.1038/s41591-018-0104-9

14. Mummadi RR, Kasturi KS, Chennareddy S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* (2008) 6:1396–402. doi: 10.1016/j.cgh.2008.08.012

15. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. *Am J Gastroenterol.* (2005) 100:1072–8. doi: 10.1111/j.1572-0241.2005.41334.x

16. Vilà-Gomès E, Martínez-Perez Y, Calzadilla-Bertoia L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology.* (2015) 149:367–78. doi: 10.1053/j.gastro.2015.04.005

17. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet.* (2015) 385:956–65. doi: 10.1016/s0140-6736(14)61933-4

18. FDA. Safety Announcement: “FDA Adds Boxed Warning to Highlight Correct Dosing of Ocaliva (Obeticholic Acid) for Patients With a Rare Chronic Liver Disease” Released on 1 Feb. Washington, DC: US Food and Drug Administration (2018).
Du W, Wei YH, Zhao G, Qin HY, Wu XA. Determination of tanshinone IIA in rat plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. J Chromatogr Sci. (2008) 46:730–4. doi: 10.1093/chromsci/46.8.730

Park EJ, Ji HY, Kim NJ, Song WY, Kim YH, Kim YC, et al. Simultaneous determination of tanshinone I, dihydrotanshinone I, tanshinone IIA, tanshinone IIB and cryptotanshinone in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study of a standardized fraction of Salvia miltiorrhiza, PF2401-SF. Biomed Chromatogr. (2008) 22:548–55. doi: 10.1002/bmc.968

Liu Y, Li X, Li Y, Wang L, Xue M. Determination of danshensu, rosmarinic acid, cryptotanshinone, tanshinone IIA, tanshinone IIB and dihydrotanshinone I by liquid chromatography-mass spectrometry and the application to pharmacokinetics in rats. J Pharm Biomed Anal. (2010) 53:698–704. doi: 10.1016/j.jpba.2010.03.041

Xing L, Tan ZR, Cheng JL, Huang WH, Zhang W, Deng W, et al. Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers. Sci Rep. (2017) 7:4709. doi: 10.1038/s41598-017-02747-4

Sun H, Yang M, Wang XM, Xu M, Liu AH, Guo DA. Identification of tanshinones and their metabolites in rat bile after oral administration of TTE-50, a standardized extract of Salvia miltiorrhiza by HPLC-ESI-MSn. J Pharm Biomed Anal. (2007) 44:564–74. doi: 10.1016/j.jpba.2006.11.003

Bi HC, Zuo Z, Chen X, Xu CS, Wen YY, Sun HY, et al. Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases. Xenobiota. (2008) 38:185–222. doi: 10.1002/00492850701.767675

Wang M, Dai H, Li X, Li Y, Wang L, Xue M. Structural elucidation of metabolites of tanshinone I and its analogue dihydrotanshinone I in rats by HPLC-ESI-MSn. J Chromatogr B Anal Technol Biomed Life Sci. (2010) 878:915–24. doi: 10.1016/j.jchromb.2010.02.014

Zhao WJ, Huang MR, Shang ZP, Wang ZL, Wang ZB, Zhang JY. Metabolites of tanshinone I and tanshinone IIA in vivo in rats. China J Chin Mater Med. (2018) 43:174–82. doi: 10.15940/cnki.cjcm.2018.0005

Ashour AA, Ramadan AA, Abdelmoneif DA, El-Kamel AH. Enhanced oral bioavailability of tanshinone IIA using lipid nanocapsules: formulation, in-vitro appraisal and pharmacokinetics. Int J Pharmaceut. (2020) 586:119598. doi: 10.1016/j.ijpharm.2020.119598

Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech. (2015) 16:1528–7. doi: 10.1208/s12249-015-9410-3

Zhi H, Li Z, Deng Y, Qi F, Hou J, Deng W, et al. Comparative in vivo constituents and pharmacokinetic study in rats after oral administration of ultrafine granular powder and traditional decoction slices of Chinese Salvia. Biomed Chromatogr. (2019) 33:4385. doi: 10.1002/bmc.4385

Song M, Hang TJ, Zhang Z, Chen H. Effects of the coexisting diterpenoid tanshinones on the pharmacokinetics of cryptotanshinone and tanshinone IIA in rat. Eur J Pharm Sci. (2007) 32:247–53. doi: 10.1016/j.ejps.2007.07.007

Xiang X, Sha X, Su S, Zhu Z, Guo S, Yan H, et al. Simultaneous determination of polysaccharides and 21 nucleosides and amino acids in different tissues of Salvia miltiorrhiza from different areas by UV-visible spectrophotometry and UHPLC with triple quadrupole MS/MS. J Sep Sci. (2018) 41:996–1008. doi: 10.1002/jss.201700802

Han QB. Critical problems stalling progress in natural bioactive polysaccharide research and development. J Agric Food Chem. (2016) 64:4851–3. doi: 10.1021/acs.jafc.6b00493

Wang Z, Zhang H, Shen Y, Zhao X, Wang X, Wang J, et al. Characterization of a novel polysaccharide from Gardenia lucidum and its absorption mechanism in Caco-2 cells and mice model. Int J Biol Macromol. (2018) 118:320–6. doi: 10.1016/j.ijbiomac.2018.06.078

Xu X, Wang R, Gao J, Peng JY, Li H, Wang L. Progress in pharmacokinetics of polysaccharides. Chin J Clin Pharmacol Ther. (2021) 26:230–5.

Jiang YY, Li YB, Yu J, Chen H, Zhou J, Wang L, et al. Preliminary structure and bioactivities of polysaccharides SMWP-U&E isolated from Salvia miltiorrhiza bunge residue. Int J Biol Macromol. (2020) 157:430–5. doi: 10.1016/j.ijbiomac.2020.04.092

Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med. (1996) 20:933–56. doi: 10.1016/0891-5849(95)02227-9

Zheng X, Kadir A, Zheng G, Jin P, Qin D, Maiwulanjiang M, et al. Antiproliferative abietane quinone diterpenoids from the roots of Salvia deserta. Bioorganic Chem. (2020) 104:104261. doi: 10.1016/j.bioxorg.2020.104261

Manach C, Mazur A, Scalbert A. Polyphenols and prevention of cardiovascular diseases. Curr Opin Lipidol. (2005) 16:77–84. doi: 10.1097/00005433-200502000-00013

Huang YY, Chen HG, Xie W, Tang T, Zhao C, Gong XJ, et al. Interaction between polysaccharide and intestinal flora and its structure effect relationship—a review. Chin Soc Microbial. (2022) 1–29

Shi B, Li Q, Feng Y, Dai X, Zhao R, Zhao Y, et al. Pharmacokinetics of 13 active components in a rat model of middle cerebral artery occlusion after intravenous injection of radix salviae miltiorrhiza-lignum dalbergiae
81. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in non-alcoholic fatty liver disease. *J Hepatol*. (2021) 74:588–69. doi: 10.1016/j.jhep.2021.02.019

82. Kahleova H, Rembert E, Alwarith J, Yonas WN, Tura A, Holubkov R, et al. Altered UDP-glucuronosyl-transferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. *Drug Metab Disposit.* (2013) 41:534–61. doi: 10.1016/j.dmd.2012.04.039

83. Francque S, Verrijken A, Caron S, Prawitt J, Paumelle R, Derudas B, et al. Experimental non-alcoholic fatty liver disease in ApoE−/− mice fed with HFD. *Evid Based Complement Altern Med.* (2021) 2021:9253281. doi: 10.1155/2021/9253281

84. Cao W, Zhang F, Xu Y, Shen L, Huang J, Xu S, Li J, et al. GuanXinNing tablet attenuates Alzheimer’s disease via improving gut microbiota, host metabolites, and neuronal apoptosis in rabbits. *Evid Based Complement Altern Med.* (2021) 2021:9253281. doi: 10.1155/2021/9253281

85. Wang L, Wang R, Wei GY, Wang SM, Du GH. Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice. *Biomed Pharmacother.* (2020) 128:110262. doi: 10.1016/j.biopha.2020.110262

86. Xue P, Hong F, Wang J, Wang J, Zhao X, Wang S, et al. DBZ is a putative PPARγ agonist that promotes high fat diet-induced obesity, insulin resistance and gut dysbiosis. *Biochim Biophys Acta Gen Subj.* (2018) 1861:2690–701. doi: 10.1016/j.bbagrm.2017.07.013

87. Saad MJ, Santos A, Prado PO. Linking gut microbiota and inflammation to obesity and insulin resistance. *Physiology (Bethesda).* (2016) 31:283–93. doi: 10.1152/physiol.00041.2015

88. Kahleova H, Rembert E, Alwarith J, Yonas WN, Tura A, Holubkov R, et al. Effects of a low-fat vegan diet on gut microbiota in overweight individuals and relationships with body weight, body composition, and insulin sensitivity. A randomized clinical trial. *Nutrients.* (2020) 12:2917. doi: 10.3390/nu120902917

89. Wang L, Wang R, Wei GY, Wang SM, Du GH. Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice. *Biomed Pharmacother.* (2020) 128:110262. doi: 10.1016/j.biopha.2020.110262

90. Liao J, Xie X, Gao J, Zhang Z, Qu F, Cui H, et al. Jian-Gan-Xiao-Zhi decoction alleviates inflammatory response in non-alcoholic fatty liver disease model rats through modulating gut microbiota. *Evid Based Complement Altern Med.* (2021) 2021:552755. doi: 10.1155/2021/552755

91. Zhao X, Chen Y, Li L, Zhai J, Yu B, Wang H, et al. Effect of DLT-SML on chronic stable angina through ameliorating inflammation, correcting dyslipidemia, and regulating gut microbiota. *Cardiovasc Pharmacol.* (2021) 77:458–69. doi: 10.1097/FPC.0000000000000770

92. Zhang F, Xu Y, Shen L, Huang J, Xu S, Li J, et al. GuanXinNing tablet attenuates Alzheimer's disease via improving gut microbiota, host metabolites, and neuronal apoptosis in rabbits. *Evid Based Complement Altern Med.* (2021) 2021:9253281. doi: 10.1155/2021/9253281

93. Cao W, Chin Y, Chen X, Mi Y, Xu C, Wang Y, et al. The role of gut microbiota in the resistance to obesity in mice fed a high fat diet. *Int J Food Sci Nutr.* (2019) 1:1–11.

94. Zhang H, Li C, Xin Y, Cui X, Cui J, Zhou G. Suppression of NSDL attenuates adipogenesis with a downregulation of LXR-SREBP1 pathway in 3T3 L1 cells. *Biochim Biophys Acta Biochim Biophys Acta Biophysics.* (2020) 1480:980–9. doi: 10.1016/j.bpb.2018.12.019

95. Meng Z, Meng L, Wang K, Li J, Cao X, Wu J, et al. Enhanced hepatic targeting, biodistribution and antibiflucenic efficacy of tanshinone IIA loaded globin nanoparticles. *Eur J Pharm Sci.* (2015) 73:35–43. doi: 10.1016/j.ejps.2015.03.002

96. Li Q, Wang Y, Feng N, Fan Z, Sun J, Nan Y. Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatitis. *J Drug Target.* (2008) 16:725–32. doi: 10.1080/10611860802374303

97. Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. *Nat Rev Gastroenterol Hepatol.* (2020) 17:279–97. doi: 10.1038/s41575-020-0269-9

98. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. *Nat Rev Gastroenterol Hepatol.* (2016) 13:412–25. doi: 10.1038/nrgastro.2016.85

99. Gu JF, Su SL, Guo JM, Zuo Y, Zhao M, Duan JA. The aerial parts of *Salvia miltiorrhiza* Bge. strengthen intestinal barrier and modulate gut microbiota imbalance in streptozocin-induced diabetic mice. *J Funct Foods.* (2017) 36:362–74. doi: 10.1016/j.jff.2017.06.010

100. Wang K, Yang Q, Ma Q, Wang B, Wan Z, Chen M, et al. Protective effects of salvianolic acid A against dextran sodium sulfate-induced acute colitis in rats. *Nutrients.* (2018) 10:791. doi: 10.3390/nu10060791

101. Zheng J, Chen M, Ye C, Sun X, Jiang N, Zou X, et al. BuZangTongLuo decoction improved hindlimb ischemia by activating angiogenesis and regulating gut microbiota in diabetic mice. *J Ethnopharmacol.* (2020) 248:112330. doi: 10.1016/j.jep.2019.112330

102. Tan Y, Li Y, Zhou F, Guo J, Wang T, Shi Y, et al. Administration of a mixture of triterpenoids from yeyachun and phenolic acids from dansen ameliorates carbon tetrachloride-induced liver fibrosis in mice by the regulation of intestinal flora. *J Pharmocol Sci.* (2020) 143:165–75. doi: 10.1016/j.jps.2020.04.007

103. Xu P, Hong F, Wang J, Wang J, Zhao X, Wang S, et al. DBZ is a putative PPARγ agonist that promotes high fat diet-induced obesity, insulin resistance and gut dysbiosis. *Biochim Biophys Acta Gen Subj.* (2016) 1861:2690–701. doi: 10.1016/j.bbagrm.2017.07.013

104. Saad MJ, Santos A, Prado PO. Linking gut microbiota and inflammation to obesity and insulin resistance. *Physiology (Bethesda).* (2016) 31:283–93. doi: 10.1152/physiol.00041.2015

105. Kakhova H, Bemberg E, Alwarith J, Yonas WN, Tura A, Holubkov R, et al. Effects of a low-fat vegan diet on gut microbiota in overweight individuals and relationships with body weight, body composition, and insulin sensitivity. A randomized clinical trial. *Nutrients.* (2020) 12:2917. doi: 10.3390/nu120902917

106. Wang L, Wang R, Wei GY, Wang SM, Du GH. Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice. *Biomed Pharmacother.* (2020) 128:110262. doi: 10.1016/j.biopha.2020.110262

107. Liao J, Xie X, Gao J, Zhang Z, Qu F, Cui H, et al. Jian-Gan-Xiao-Zhi decoction alleviates inflammatory response in non-alcoholic fatty liver disease model rats through modulating gut microbiota. *Evid Based Complement Altern Med.* (2021) 2021:552755. doi: 10.1155/2021/552755
109. Mukohda M, Lu KT, Guo DF, Wu J, Keen HL, Liu X, et al. Hypertension- 
correlation mutation in peroxisome proliferator-activated receptor γ impairs 
nuclear export of nuclear factor-κB p65 in vascular smooth muscle. 
Hypertension. (2017) 70:174–82. doi: 10.1161/HYPERTENSIONAHA.117. 
09276
110. Yoo SH, Park O, Henderson LE, Abdelmegeed MA, Moon KH, Song BJ. 
Lack of PPARα exacerbates lipopolysaccharide-induced liver toxicity through 
STAT1 inflammatory signaling and increased oxidative/nitrosative stress. 
Toxicol Lett. (2011) 202:23–9. doi: 10.1016/j.toxlet.2011.01.013
111. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in 
the prevention of cardiovascular disease-a pooled meta-analysis of long-term 
randomized placebo-controlled clinical trials. Am Heart J. (2007) 154:943–53. 
doi: 10.1016/j.ahj.2007.07.011
112. Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K, et al. 
Adipocytokine regulation and antiangiogenic activity underlie the 
molecular mechanisms of therapeutic effects of 
Phyllanthus niruri against non-
alcoholic fatty liver disease. J Hepatol. (2015) 63:543–53. 
doi: 10.1016/j.jhep.2012.05.019
113. Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ. Critical 
role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-
induced fatty liver disease. Hepatology. (2017) 65:3032–44. doi: 10.1001/bgh. 
13933
114. Pan X, Wang P, Luo J, Wang Z, Song Y, Ye J, et al. Adipogenic changes 
in response to the FXR agonist obeticholic acid. Arch Toxicol. (2016) 19:67959. 
doi: 10.1007/s00204-014-1348-x
115. Janssen AWF, Assl M, Al-Mansoub MA, Mohamed Z, Ahmad M, et al. Adipocytokine regulation and antiangiogenic activity underlie the 
molecular mechanisms of therapeutic effects of 
Phyllanthus niruri against non-
alcoholic fatty liver disease. J Hepatol. (2015) 63:543–53. 
doi: 10.1016/j.jhep.2012.05.019
116. Zarzour RHA, Alshawsh MA, Asif M, Al-Mansoub MA, Mohamed Z, Ahmad 
M, et al. Adipocytokine regulation and antiangiogenic activity underlie the 
molecular mechanisms of therapeutic effects of 
Phyllanthus niruri against non-
alcoholic fatty liver disease. J Hepatol. (2015) 63:543–53. 
doi: 10.1016/j.jhep.2012.05.019
117. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile 
acid homeostasis. J Hepatol. (2015) 70:174–82. doi: 10.1016/j.jhep.2013.05.042
118. Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, et al. Liver X receptor in cooperation with SREBP-1c is a major liver synthesis 
regulator in nonalcoholic fatty liver disease. Hepatol Res. (2008) 38:1122–9. 
doi: 10.1111/j.1872-034X.2008.00382.x
119. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L. Challenges and 
opportunities in drug and biomarker development for nonalcoholic 
steatohepatitis. J Gastroenterol Hepatol. (2013) 28:303–9. doi: 10.1111/j.1440-
8625.2012.05704.x
120. Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty 
liver disease. Curr Atheroscler Rep. (2015) 17:462. doi: 10.1007/s11883-015-
0500-2
121. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, et al. Activation 
inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, et al. 
Oleanolic acid inhibits liver X receptor alpha and pregnane X receptor to attenuate 
lipoprotein lipogenesis. J Agric Food Chem. (2018) 66:10964–76. doi: 10. 
1021/acs.jafc.8b03372
122. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. (2000) 16:459– 
81. doi: 10.1146/annurev.cellbio.16.1.459
123. Higuchi N, Kato M, Shundo Y, Tajiri H, Tanaka M, Yamashita N, et al. Liver X receptor in cooperation with SREBP-1c is a major liver synthesis 
regulator in nonalcoholic fatty liver disease. Hepatol Res. (2015) 38:1122–9. 
doi: 10.1111/j.1872-034X.2008.00382.x
124. Gu M, Zhang Y, Liu C, Wang D, Feng L, Fan S, et al. Morin, a novel liver X 
receptor α/β dual antagonist, has potent therapeutic efficacy for nonalcoholic 
fatty liver diseases. Br J Pharmacol. (2017) 174:3032–44. doi: 10.1111/bph. 
13933
125. Lin YN, Chang HY, Wang CCN, Chu FY, Shen HY, Chen CJ, et al. Oleanolic 
acid inhibits liver X receptor alpha and pregnane X receptor to attenuate 
lipoprotein lipogenesis. J Agric Food Chem. (2018) 66:10964–76. doi: 10. 
1021/acs.jafc.8b03372
steatohepatitis: findings and recommendations from an American association for the study of liver diseases-U.S food and drug administration joint workshop. Hepatology. (2015) 61:1392–405. doi: 10.1002/hep.27678

144. Lyu J, Xue M, Li J, Lya W, Wen Z, Yao P, et al. Clinical effectiveness and safety of salvia miltiorrhiza dipside salt combined with aspirin in patients with stable angina pectoris: a multicenter, pragmatic, randomized controlled trial. Phytomedicine. (2021) 81:153419. doi:10.1016/j.phymed.2020.153419

145. Lee HS, Son WC, Ryu JE, Koo BA, Kim YS. Standardized Salvia miltiorrhiza extract suppresses hepatic stellate cell activation and attenuates steatohepatitis induced by a methionine-choline deficient diet in mice. Molecules. (2014) 19:8189–211. doi: 10.3390/molecules19068189

146. Ding C, Zhao Y, Shi X, Zhang N, Zu G, Li Z, et al. New insights into salvinianolic acid A action: regulation of the TXNIP/NLRP3 and TXNIP/ChREBP pathways ameliorates HFD-induced NAFLD in rats. Sci. Rep. (2016) 6:28734. doi: 10.1038/srep28734

147. Lee MM, Kim HG, Lee SB, Lee JS, Kim WY, Choi SH, et al. C4plus, a standardized herbal composition ameliorates non-alcoholic steatohepatitis in a tunicamycin-induced mouse model. Phytomedicine. (2018) 41:24–32. doi: 10.1016/j.phymed.2018.01.020

148. Zhang XJ, Tian Y. Efficacy and safety of Alovastatin combined with compound Danshen tablets in the treatment of non-alcoholic fatty liver disease. Liver. (2019) 24:839–41.

149. Park II, Yang WK, Nam SH, Hong I, Yang KR, Kim J, et al. Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma. Apoptosis. (2014) 14:615–28. doi:10.1007/s10495-013-0929-0

150. Zhang X, Ma Z, Liang Q, Tang X, Hu D, Liu C, et al. Tanshinone IIA exerts protective effects in a LCA-induced cholestatic liver model associated with participation of pregnane X receptor. J Ethnopharmacol. (2015) 164:357–67. doi: 10.1016/j.jep.2015.01.047

151. Yang MD, Chiang YM, Higashiyama R, Asahina K, Mann DA, Mann J, et al. Rosmarinic acid and baicilgenic epigallocatechin gallate inhibit proliferation of human keratinocyte and breast cancer cells: a potential anticancer strategy. J Ethnopharmacol. (2007) 113:210–7. doi: 10.1016/j.jep.2006.04.044

152. Li GH, Li YR, Jiao P, Zhao Y, Hu HX, Lou HX, et al. Therapeutic Potential of Salvia miltiorrhiza radix et rhizoma against human diseases based on activation of Nrf2-mediated antioxidant defense system: bioactive constituents and mechanism of action. Oxid Med Cell Longev. (2018) 2018:7309073. doi: 10.1155/2018/7309073

153. Mahesh R, Jung HW, Kim GW, Park YK. Cryptotanshinone from Salvia miltiorrhiza radix inhibits sodium-nitroprusside-induced apoptosis in neuro-2a cells. Salviae miltiorrhizae radix inhibits sodium-nitroprusside-induced apoptosis in neuro-2a cells. J Ethnopharmacol. (2008) 117:5479–87. doi: 10.1016/j.jep.2008.10.002

154. Lv Z, Song Y, Xue D, Zhang W, Cheng Y, Xu L. Effect of salvianolic acid B on inhibiting MAPK signaling induced by transforming growth factor-β1 in activated rat hepatic stellate cells. J Ethnopharmacol. (2010) 132:384–92. doi: 10.1016/j.jep.2010.05.026

155. Wang R, Yu XJ, Guo ZY, Wang YJ, Wu Y, Yuan YF. Inhibitory effects of salvianolic acid B on CCl4-induced hepatic fibrosis through regulating NF-κB/IκB signaling. J Ethnopharmacol. (2012) 144:592–8. doi: 10.1016/j.jep.2012.09.048

156. Ye P, Guo Y, Chen B, Shi L, Dong P, Zhou M, et al. LncRNA-p21 Inhibits the Wnt/β-catenin pathway in activated hepatic stellate cells via sponging microRNA-17-5p. Cell Physiol Biochem. (2017) 41:1970–80. doi: 10.1159/000472410

157. Zhu J, Wang R, Xu T, Zhang S, Zhao Y, Li Z, et al. Salvianolic acid A attenuates endoplasmic reticulum stress and protects against cholesterol-induced liver fibrosis via the SIRT1/HSF1 pathway. Front Pharmacol. (2018) 9:1227. doi: 10.3389/fphar.2018.01277

158. Wang W. Study on the Prevention and Treatment Effects and Mechanism of Lactobacillus plantarum, Bifidobacterium bifidum and Salvia miltiorrhiza Polysaccharides on Non-alcoholic Fatty Liver Disease. Guangzhou: Southern Medical University (2020).
178. Browning JD, Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans. *J Lipid Res.* (2010) 51:3359–63. doi: 10.1194/jlr.P0 09860

179. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. *J Biol Chem.* (2010) 285:33652–61. doi: 10.1074/jbc.M110. 152090

180. Jia L, Song N, Yang G, Ma Y, Li X, Li R, et al. Effects of tanshinone IIa on the modulation of miR-33a and the SREBP2/PSek9 signaling pathway in hyperlipidemic rats. *Mol Med Rep.* (2016)13:4627–35. doi: 10.3892/mmr.2016. 5133

181. Xie Z, Loi Truong T, Zhang P, Xu F, Xu X, Li P. Dan-Qi prescription ameliorates insulin resistance through overall corrective regulation of glucose and fat metabolism. *Eur Pharmacol.* (2015) 727:70–9. doi: 10.1016/j.ejpb.2015.05.041

182. Chen Q, Wang T, Li J, Wang S, Qiu F, Yu H, et al. Effects of natural products on fructose-induced nonalcoholic fatty disease (NAFLD). *Nutrients.* (2017) 9:96. doi: 10.3390/nu9090096

183. Zhang N, Hu Y, Ding C, Zeng W, Shan W, Fan H, et al. Salvinolic acid B protects against chronic alcoholic liver injury via SIRT1-mediated inhibition of CRP and ChREBP in rats. *Toxicol Lett.* (2017) 267:1–10. doi: 10.1016/j.toxlet.2016.12.010

184. Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. *J Clin Investig.* (2012) 122:2176–94. doi: 10.1172/JCI41636

185. Chen J, Deng J, Zhang Y, Yang J, He Y, Fu W, et al. Lipid-lowering effects of Danshen injection on hyperlipidemia rats. *Eur Pharmacol.* (2014) 154:437– 42. doi: 10.1016/j.ejphar.2014.04.023

186. Dou X, Li S, Wang Z, Gu D, Shen C, Yao T, et al. Inhibition of NF-κB activation by 4-hydroxynonenal contributes to liver injury in a mouse model of alcoholic liver disease. *Am J Pathol.* (2012) 181:1702–10. doi: 10.1016/j.ajpath.2012.08.004

187. Ding L, Wu L, Du Z, Tang L, Song Z, Dou X. Danshen protects against early-stage alcoholic liver disease in mice via inducing PPARα activation and subsequent 4-HNE degradation. *PLoS One.* (2017) 12:e0186357. doi: 10.1371/journal.pone.0186357

188. Ilpenberg A, Tan NS, Gelman L, Kersten S, Seydoux J, Xu J, et al. In vivo activation of PPAR target genes by KKR homodimers. *EMBO J.* (2004) 23:2083–91. doi: 10.1038/sj.emboj.7600209

189. Yin HQ, Kim YS, Choi YJ, Kim YC, Sohn DH, Ryu SY, et al. Effects of tanshinone IIa on the hepatotoxicity and gene expression involved in alcoholic liver disease. *Arch Pharm Res.* (2008) 31:659–65. doi: 10.1007/s12272-001-1209-2

190. Wang X, Qi D, Fu F, Li X, Liu Y, Ji K, et al. Therapeutic and antiproteinuric effects of salvinolic acid A in combined with low-dose prednisone in minimal change disease rats: involvement of PPARγ/Anpgrp and Nrf2/HO-1 pathways. *Eur J Pharmacol.* (2019) 858:172342. doi: 10.1016/j.ejphar.2019.04.023

191. Pi J, Leung L, Xue P, Wang W, Hou Y, Liu D, et al. Deficiency in the nuclear factor E2-related factor-2 transcription factor results in impaired adipogenesis and protects against diet-induced obesity. *J Biol Chem.* (2010) 285:29292–300. doi: 10.1074/jbc.M110.093955

192. Zhu NL, Wang J, Tsukamoto H. The Necdin-Wnt pathway causes epigenetic activation by 4-hydroxynonenal contributes to liver injury in a mouse model of alcoholic substances. *Curr Mol Pharmacol.* (2014) 7:535–44. doi: 10.2174/18744666140701411111114

193. Jamwal R, Barlock BJ. Nonalcoholic fatty liver disease (NAFLD) and hepatic cytochrome CYP3A4 (CYP) enzymes. *Pharmaceuticals.* (2020) 13:122. doi: 10.3390/ph13090222

194. Jamwal R, de la Monte SM, Ogasaewara K, Adusumalli S, Barlock BR, Akhlaghi F. Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver. *Mol Pharm.* (2018) 15:2621–32. doi: 10.1021/acs.molpharmaceut.8b00159

195. Rahman N, Leon M, Song HY, Kim YS. Cryptotanshinone, a compound of Salvia miltiorrhiza inhibits pre-adipocyte differentiation by regulation of adipogenesis-related genes expression via STAT3 signaling. *Phytomedicine.* (2016) 23:58–67. doi: 10.1016/j.phymed.2015.12.004

196. Sung HY, Jun JG, Kang SW, Kim HS, Shin D, Kang JJ, et al. Novel danshen methoxybenzo[b]furan derivative antagonizing adipogenic differentiation and production of inflammatory adipokines. *Chem Biol Interact.* (2010) 188:457– 66. doi: 10.1016/j.cbi.2010.09.017

197. Byun JW, Hwang S, Kang CW, Kim JH, Chae MK, Yoon JS, et al. Therapeutic effect of protocatechue aldehyde in an in vitro model of Graves’ orbitopathy. *Invest Ophthalmol Vis Sci.* (2017) 57:4055–62. doi: 10.1167/iovs.15-19037

198. Huang C, Zhang Y, Li Q, Wang MW, et al. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonist. *Endocrinology.* (2009) 150:104–13. doi: 10.1210/en.2008-0322
215. Wu QB. Magnesium isoglycyrrhizinate combined with Salvia miltiorrhiza in treating non-alcoholic fatty hepatitis control observation. *J Pract Trad Chin Med.* (2012) 26:41–2.

216. Wu H, Chen Jf. Treatment of 32 cases of non-alcoholic fatty liver disease with reduced glutathione and Salvia miltiorrhiza injection. *Chin J Integr Trad Western Med Digest.* (2010) 18:400–1.

217. Shao SQ. Tiopronin combined with Salvia miltiorrhiza injection in the treatment of non-alcoholic steatohepatitis. *Clin Med.* (2005) 9:59–60.

218. Fan HX, Lv LS. Effect of compound danshen dripping pill combined with polyene phosphatidyl choline in treatment of non-alcoholic fatty liver disease. *Drug Eval Res.* (2017) 40:1327–30.

219. Tsuchida T, Lee YA, Fujisawa N, Ybanez M, Allen B, Martins S, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. *Hepatology.* (2018) 69:385–95. doi: 10.1002/hep.29735.003

220. Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic fatty liver disease. *Hepatology.* (2018) 68:230–7.

221. Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease-A starter’s guide. *Nutrients.* (2017) 9:1072. doi: 10.3390/nu9101072

222. Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology.* (2020) 158:1999–2014.e1. doi: 10.1053/j.gastro.2019.11.312

223. Tanaka N, Aoyama T, Kimura S, Gonzalez FJ. Targeting nuclear receptors for the treatment of fatty liver disease. *Pharmacol Ther.* (2017) 179:142–57. doi: 10.1016/j.pharmthera.2017.05.011

224. Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, et al. Best practice in research-Overcoming common challenges in phytopharmacological research. *J Ethnopharmacol.* (2020) 246:112230. doi: 10.1016/j.jep.2019.112230

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the editor, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liu, Shi, Peng, Wang, Yu, Wang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.